1. An automated method for the simultaneous determination of pravastatin and its main metabolite in human plasma by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry
- Author
-
Kiyoshi Kawabata, Kunihiro Sasahara, and Nobuko Matsushima
- Subjects
Clinical Biochemistry ,Analytical chemistry ,Atmospheric-pressure chemical ionization ,Mass spectrometry ,Sensitivity and Specificity ,Biochemistry ,High-performance liquid chromatography ,Mass Spectrometry ,Sample preparation in mass spectrometry ,Analytical Chemistry ,Automation ,Liquid chromatography–mass spectrometry ,Drug Discovery ,Humans ,Selected ion monitoring ,Direct electron ionization liquid chromatography–mass spectrometry interface ,Molecular Biology ,Chromatography, High Pressure Liquid ,Pravastatin ,Pharmacology ,Chemical ionization ,Chromatography ,Chemistry ,Anticholesteremic Agents ,Reproducibility of Results ,General Medicine ,Atmospheric Pressure - Abstract
A new method for the determination of pravastatin, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, and its main metabolite (R-416) in human plasma using high-performance liquid chromatography/atmospheric pressure (negative ion) chemical ionization mass spectrometry (LC/APCI-MS) is described. Pravastatin and R-416 in human plasma were isolated using solid phase extraction technique and analyzed by LC/APCI-MS. Selected ion monitoring was employed for selectivity and sensitivity, which enabled the quantification over a range of 0.625-80 mg/mL with acceptable precision and accuracy. No derivatization was required for these polar molecules. The retention times of the pravastatin, R-416 and the internal standard (R-1437) were 2.1, 2.5 and 3.9 min, respectively, with a total analysis time of 5 min. This method was validated and compared with the automated gas chromatography/negative ion chemical ionization mass spectrometry procedure.
- Published
- 1998
- Full Text
- View/download PDF